Department of Epidemiology, Shandong University, Jinan, Shandong, People's Republic of China.
J Public Health (Oxf). 2018 Jun 1;40(2):e126-e132. doi: 10.1093/pubmed/fdx056.
To assess the effect of treatment on limiting weight gain in abstainers using and not using varenicline and during the nontreatment phase.
The PubMed, Medline, EMBASE and Cochrane Library databases were searched to identify relevant studies published in English or Chinese. A meta-analysis was performed to calculate pooled weighted mean differences (WMDs) in weight gain in smokers after smoking cessation between varenicline and control groups and their corresponding 95% CIs. The I2 statistic was used to measure heterogeneity. Publication bias was evaluated using Egger's regression asymmetry test.
A total of 10 studies were included. The WMD in weight gain in abstainers between varenicline and control groups was -0.23 kg (95% CI: -0.36 to -0.09, P < 0.05). Moreover, the result of the subgroup analysis by timepoint of weight measurement indicated that the WMD in weight gain in smokers after smoking cessation between varenicline and control groups after the 12-week treatment phase was -0.23 kg (95% CI: -0.37 to -0.08, P < 0.05), and the WMD observed during the nontreatment follow-up phase was -0.69 kg (95% CI: -2.15 to 0.77, P > 0.05). In addition, the result of the subgroup analysis by type of control showed that the WMD in weight gain in abstainers from smoking between the varenicline and placebo groups was -0.29 kg (95% CI: -0.46 to -0.12, P < 0.05), and the WMD between the varenicline and other control groups was -0.20 kg (95% CI: -0.77 to 0.37, P > 0.05).
Varenicline was associated with a modest limitation in weight gain in smokers after smoking cessation; however, the impact of varenicline use was not long-term, and, in fact, no different from that of the placebo treatment.
评估使用和不使用伐伦克林的戒烟者在治疗期间和非治疗期间限制体重增加的效果。
检索 PubMed、Medline、EMBASE 和 Cochrane 图书馆数据库，以确定发表在英文或中文的相关研究。对戒烟后吸烟者使用伐伦克林和对照组之间体重增加的加权均数差（WMD）进行荟萃分析，并计算其相应的 95%置信区间（CI）。采用 I2 统计量衡量异质性。采用 Egger 回归不对称检验评估发表偏倚。
共纳入 10 项研究。伐伦克林组和对照组在戒烟者体重增加方面的 WMD 为-0.23kg（95%CI：-0.36 至-0.09，P<0.05）。此外，按体重测量时间点的亚组分析结果表明，在 12 周治疗阶段后，伐伦克林组和对照组戒烟者在戒烟后体重增加的 WMD 为-0.23kg（95%CI：-0.37 至-0.08，P<0.05），而在非治疗随访阶段的 WMD 为-0.69kg（95%CI：-2.15 至 0.77，P>0.05）。此外，按对照组类型的亚组分析结果表明，伐伦克林组和安慰剂组戒烟者体重增加的 WMD 为-0.29kg（95%CI：-0.46 至-0.12，P<0.05），而伐伦克林组和其他对照组之间的 WMD 为-0.20kg（95%CI：-0.77 至 0.37，P>0.05）。
伐伦克林可适度限制戒烟后吸烟者的体重增加；然而，伐伦克林的使用效果并不持久，实际上与安慰剂治疗无差异。
